Despite efforts to develop vaccines that protect against malaria by inducing CD8 + T cells that kill infected hepatocytes, no subunit vaccine has been shown to circumvent the genetic restriction inherent in this approach, and little is known about the interaction of subunit vaccineinduced immune effectors and infected hepatocytes. We now report that immunization with plasmid DNA encoding the Plasmodium yoelii circumsporozoite protein protected one of five strains of mice against malaria (H-2 a, 75%); a PyHEP17 DNA vaccine protected three of the five strains (H-2 a, 71%; H-2 k, 54%; H-2 a, 26%); and the combination protected 82% of H-2 a, 90% of H-2 k, and 88% of H-2 a mice. Protection was absolutely dependent on CD8 + T cells, IFN-~/, or nitric oxide. These data introduce a new target of protective preerythrocytic immune responses, PyHEP17 and its P. falciparum homologue, and provide a realistic perspective on the opportunities and challenges inherent in developing malaria vaccines that target the infected hepatocyte.
I
mmunization with radiation-attenuated Plasmodium spp. .sporozoites induces sterile protective immunity against malaria in rodents, primates, and humans (for review see reference l). Protection is dependent on CD8 § T cells in some rodent models (2, 3) , and CD8 + T cells can protect in the absence of other immune responses (4) (5) (6) (7) . Immunity is presumably mediated via CD8 + T cell recognition of parasite-derived peptides that are presented on the surface of infected hepatocytes in association with class I MHC molecules; hepatocytes are the only cell in the parasite's fife cycle known to express class I MHC molecules. That CD8 + CTLs can recognize an epitope from the Plasmodium yoelii circumsporozoite protein (PyCSP) 1 expressed on P. yoeliiinfected hepatocytes (8) , and that MHC-restricted immunemediated elimination of infected hepatocytes that are expressing parasite Ags can protect against sporozoite-transmitted malaria (9) have been demonstrated. Accordingly, there have been efforts to develop subunit vaccines that induce protective CD8 + T cells. To be effective in a heterogeneous population, however, such vaccines must contain multiple protective CD8 + T cell epitopes restricted by diverse class I tAbbreviations used in this paper: CSP, circumsporozoite protein; HEP, hepatocyte erythrocyte protein; PyCSP, Plasmodium yoelii CSP; PyHEP17, Plasmodium yoelii hepatocyte erythrocyte protein 17.
MHC alleles (10, 11) . Only a few of such epitopes have been identified in mice, and all have been on the H-2 a background (4-7), and subunit vaccine-induced CD8 + T cell-dependent protection has only been demonstrated in H-2 a mice. Furthermore, it is not known whether the CD8 + T cells lyse the infected hepatocytes directly, as classical CTLs (for review see reference 12) , or indirectly via mediators such as cytokines that induce the infected hepatocyte to inactivate or kill the parasite. It has been estabfished, however, that IFN-~/is active against infected hepatocytes (2, 6, (13) (14) (15) (16) (17) . Reports indicate that IFN-~ produced by CD8 + T cells induces infected hepatocytes to produce L-arginine-derived nitrogen oxides that are toxic to the intracellular parasite (18) (19) (20) (21) (22) .
The irradiated sporozoite vaccine is impractical for largescale human use, and progress in developing subunit vaccines that induce protection comparable to that induced by the irradiated sporozoite vaccine has been slow (for review see reference 1). We recently reported (23) that immunization of BALB/c mice with plasmid DNA encoding the PyCSP induces more potent in vitro cytolytic activity against a nonamer epitope on the PyCSP than does immunization with irradiated sporozoites and induces CD8 + T cell-dependent protection. These data raise crucial issues concerning the efficacy of the PyCSP DNA vaccine on non-BALB/c backgrounds as a consideration for human trials, and the host effector mechanisms responsible for the DNA-induced protective immunity.
We Antibodies. Purified rat Ig was purchased from Rockland,
Inc. The anti-CD4 + mAb GK1.5 (rat IgG2a) was obtained from ATCC (TIB207) and has been previously described (27) . The anti-CD4 + mAb YTA3.1.2 (rat IgG2b) was provided by Dr. H. Waldmann and has been previously described (28) . The anti-CD8 + mAb 2.43 (mouse IgG2a) was obtained from ATCC (TIB210) and has been previously described (29) . The anti-IFN-~./ mAb XMG-6 (rat IgG1) was provided by Dr. F. Finkelman and has been previously described (30) . All Igs were purified from ascites (Harlan Bioproducts for Science, Indianapolis, IN) by 50% ammonium sulphate precipitation, and final Ab concentrations were determined by optical density.
Depletions. Immunized mice were treated as follows. Unde- Serology. Mice were bled for serum ,--,2 wk after each immunization. Sera were assayed by indirect fluorescent Ab test against air-dried P. yoelii sporozoites, liver-stage parasites, or bloodstage parasites as previously described (31) .
Results

PyCSP DNA Vaccine Protects against Malaria on a Single Genetic Background.
Both MHC and non-MHC genes con-trol protection against P. yoelii in mice (32) . Immune responses to P. falciparum, P. vivax, P. yoelii, and P. berghei CD8 + and CD4 + T cell epitopes and B cell epitopes are also known to be genetically restricted (for review see reference 33). Previously, we reported that BALB/c mice are protected against sporozoite challenge by inununization with PyCSP DNA (23) . We wanted to assess the capacity of PyCSP DNA to confer protection in mice of other genetic backgrounds. Five inbred mouse strains were selected for the immunization studies on the basis of differences in both genetic background and H-2 haplotypes: BALB/ cByJ (H-2KalaDaLa); A/J (H-2KkIkDaLa); B10.BR/SgSnJ (H-2KklkD~Lk); B10.Q/SgJ (H-2KqlqDqLq); and C57BL/ 6J, (H-2KblbDt'Lb). Only in BALB/c mice was protection >20% ( Table 1) .
The CSP is a principal candidate Ag for preerythrocytic vaccine development (34) . The data presented here predict that anti-CSP CD8 + T cell responses alone will, however, be inadequate to protect an outbred human population. A vaccine designed to protect humans by inducing CD8 + T cells that recognize 8-10 amino acid peptides complexed with class I HLA molecules on infected hepatocytes will therefore have to include epitopes from multiple parasite proteins.
PyHEPI 7 DNA Vaccine Protects against Malaria on Multiple Genetic Backgrounds. Localization of the recently identified liver-and blood-stage Ag PyHEP17 in P. yoelii-infected
hepatocytes (24) suggested that, like the CSP, this Ag may be a target of protective T cell responses directed at the in- is Lower than that used in previous studies with either the PyHEP17 DNA (200 Ixg) or PyCSP DNA (200 p,g), where no effect of the increased DNA dose was observed (data not presented).
DNA-induced Protection Is Dependent upon CD8 + T Cells.
The protective immune responses induced by the PyHEP17 DNA vaccine must be directed against the infected hepatocyte. First, immunity cannot be directed against sporozoites in the circulation, since PyHEP17 is not expressed in sporozoites and is first expressed within 6 h of sporozoite invasion of hepatocytes (24) . Second, immunity is not directed against the erythrocytic stage of the parasite life cycle, which commences when the parasites are released from infected hepatocytes, since there was no protection against challenge with 200 infected erythrocytes (data not presented). Third, sera from mice immunized with the PyHEP17 DNA did not recognize P. t, oelii liver-stage parasites and recognized P. yoelii erythrocytic-stage parasites by IFAT only at very low levels (Table 1) , and there was no correlation between Ab titers and protection against sporozoite challenge (Table 1) .
To determine whether a specific subset ofT cells was required for the DNA-induced protection, we conducted in vivo depletion studies. In six of the eight different groups of mice, CD4 + T cell depletion did not lead to any reduction in protection (Table 2 ). However, in B10.BP~ mice immunized with PyHEP17 DNA, protection was reduced from 75 to 50% by CD4 § T cell depletion, and in BALB/c mice immunized with the PyHEP17-PyCSP DNA combination, protection was reduced from 80 to 40% after CD4* depletion (Table 2 ). These data may reflect the variability of the protection after DNA immunization in general or may be indicative of a role for CD4 § T cells in DNA vaccine-induced protection in these mice. Since the reduction only occurred in two of the eight groups, and the differences were not statistically significant (Fisher's exact P value: B10.BR nfice immunized with the PyHEP17 vaccine, 0.377; BALB/c mice immunized with the combination vaccine, 0.1698), we favor the former explanation. In marked contrast, however, CD8 § T cell depletion coinpleted eliminated protection in all groups of immunized mice (Table 2) . Therefore, protective immunity after immunization with PyHEP17 DNA and with the PyHEP17-PyCSP DNA combination is entirely dependent on CD8 § T cells. Consistent with this finding, MHC-restricted Agspecific CD8 + CTLs are induced in mice by PyHEPI7
DNA immunization (Doolan, L.D., unpublished data).
DNA-induced Protection Is Dependent upon IFN-'y and Nitric Oxide.
We reasoned that DNA vaccine-induced anfi-PyCSP and PyHEP17 CD8 + T cells are eliminating infected hepatocytes, as demonstrated with irradiated sporozoite-induced CD8 § T cells (8, 9) . In vitro and in vivo data indicate that IFN-~/produced by malaria-specific CD8 + T cells stimulate Plasmodium-infected hepatocytes to eliminate the parasite by producing nitric oxide (19, 20, 22) . To determine whether the PyHEPI 7, PyCSP, or PyHEP17-PyCSP combination DNA vaccines induce the same pathway, B10.BR nfice were immunized and treated before sporozoite challenge with either anti-lFN-~/mAb or aminognanidine, an Table 2 . One mouse per group was killed on the day of challenge to assess depletion with FACScan. The efticiencies of CD4 + and CD8 + T cell depletion were estimated as 99 and 96%, respectively. inhibitor of the inducible isoform of nitric oxide synthase (iNOS) (35) . The results show that there is an absolute requirement for both IFN-~/ and nitric oxide in the DNA vaccine-induced protective immunity (Table 3) .
Discussion
The data presented here identify PyHEP17 (24) as a new target of protective immune responses directed against the infected hepatocyte and systematically define the process whereby effector CD8 + T cells induced by immunization with a single gene or bi-gene DNA malaria vaccine recognize the infected hepatocyte and eliminate the capacity of that cell to sustain a viable plasmodial infection. The data also emphasize the absolute requirement for such a vaccine to induce protective T cell responses against multiple parasite proteins if it is to be effective in a heterogeneous population.
Genetic restriction of protective CD8 + T cell responses is expected, since the T cell receptor can only recognize its target peptide when that 8-10-amino acid peptide is complexed with a class I MHC molecule, with specific amino acid restrictions on the formation of that complex (for review see reference 36). Nonetheless, we were surprised that immunization with the PyCSP DNA vaccine only protected one of five strains of inbred mice (see Table 1 ). The PyCSP gene encodes a protein of 391 amino acids and we expected, apparently inappropriately, that the PyCSP would contain protective CD8 § T cell epitopes recognized by class I MHC molecules from multiple strains of mice. Inbred mice are different from outbred humans; however, this finding certainly suggests that it may be inappropriate to construct a human malaria vaccine designed to induce protective CD8 + T cell responses directed against only the CSP.
The studies presented here demonstrate that it is possible to circumvent genetic restriction ofCD8 + T cell-mediated protective immunity against individual Plasmodium spp. proteins expressed in infected hepatocytes by immunizing with more than one protein. This may appear obvious, but there are only a few examples of this phenomenon after immunization with subunit vaccines (37) (38) (39) . Furthermore, immunization with two peptides representing defined CD8 + CTL epitopes on the CSP often leads to less cytolytic activity against either one than does immunization with the individual peptide (Franke, E.D., personal communication). Additional work is required to determine whether additive protection will be obtained with all DNA vaccines, or whether it is restricted to the responses to certain Ags.
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The irradiated sporozoite vaccine has been the model and gold standard for preerythrocytic stage malaria vaccine development. In BALB/c mice, immunization with irradiated sporozoites, but not with DNA, can confer 100% sterile protective immunity against massive sporozoite challenge (Sedegah, M., unpublished data). In contrast, Weiss et al. (32) reported that only 31% of B10.BR. mice were protected against challenege with 5,000 P. yoelii sporozoites after immunization with irradiated sporozoites; this protection was not dependent on CD8 + T cells. Here, we report that the PyCSIX-PyHEP17 combination protected 90% of B10.BR mice against challenge with 100 P. yoelii sporozoites after DNA immunization with the PyCSP-PyHEP17 combination (see Table 1 ); this protection was completely dependent on CD8 + T cells (see Table 2 ). Therefore, in B 10.BR mice, the bi-gene DNA vaccine may provide better CD8 + T cell-dependent protection against P. yoelii than does the whole organism vaccine. It is unlikely that the bi-gene DNA vaccine contains more CD8 + T cell epitopes recognized by H-2 k B10.BR mice than does the irradiated sporozoite vaccine, or that "cryptic" epitopes are exposed by DNA immunization. It is more probable that, as demonstrated for PyCSP in H-2 d BALB/c mice (23), the DNA vaccine is inducing a much more potent CD8 + T cell response against epitopes presented by both systems than is the irradiated sporozoite vaccine. Certainly, such protection may be better than that afforded by repeated exposure to malaria in the field, where sterile immunity does not occur (40) and malaria-specific CD8 + CTL responses are low (41) (42) (43) .
Despite a large literature referring to protective CD8 + CTLs (for review see reference 1), the phenomenon of classical cytolytic activity with direct contact between the effector T cell and the infected target cell and subsequent lysis of the target cell by CD8 + CTLs (for review see reference 12) has never been established in malaria. Although CSP-and sporozoite surface protein 2-specific CD8 § T cell clones with cytolytic activity can adoptively transfer protection (4-7), it is not known whether the activity against the infected hepatocytes is cytolytic. In fact, it has been shown that the protective activity of one such antiPyCSP CTL clone is abrogated by in vivo treatment of mice with anti-IFN-~/ (6), and that in two strains of mice, the protective immunity induced by immunization with irradiated P. berghei sporozoites is reversed by in vivo treatment of the mice with anti-lFN-~/ (2, 22) . The data presented here suggest that the activity of protective CD8 + T cells against Plasmodium-infected hepatocytes is not via a classical cytolytic mechanism. The protection is completely reversed by in vivo depletion of CD8 + T cells, by treatment with anti-IFN-% or by inhibiting the inducible isoform of nitric oxide synthase. We interpret these findings to indicate that the CD8 + T cell activated by interacting with the MHC-peptide complex on the surface of the infected hepatocyte secretes IFN-% The IFN-~/then induces the infected hepatocyte to produce nitric oxide that renders the parasite noninfectious. This may in part explain the multitude of reports in both rodent and human systems showing that the induction of CTLs against Plasmodium spp. proteins does not correlate with protection of the host (44) (45) (46) (47) (48) .
This study lays the foundation for multigene DNA vaccines (for reviews see references 49 and 50) designed to attack infected human hepatocytes and identifies the newly discovered P. falciparum homologne of PyHEP17 (Doolan, D.L., et al. manuscript submitted for publication) as a candidate component of any such multivalent vaccine. However, it must be placed in perspective. Some strains of mice were not protected, and all challenge work was done with a parasite clone. If there is any hope of producing long-lasting protection in heterogeneous human populations, additional genes will have to be included to overcome the MHC restriction ofT cell responses and the antigenic polymorphism of the parasite at T cell epitopes. The exquisite dependency of this protection on each of the individual effectors---CD8 + T cells, IFN-% and nitric oxide underscores the long-term complexity of developing an effective hepatocyte-targeted malaria vaccine. It seems obvious that an effective vaccine that functions by killing infected hepatocytes will have to be as complex and elegant as its parasite opponent.
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